CD
LLY icon

Chapin Davis’s Eli Lilly LLY Stock Holding History

Chapin Davis’s Portfolio LLY Stock Details LLY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.1M Sell
1,749
-1,102
-39% -$1.13M 0.37% 51
2026
Q1 		$2.62M Buy
2,851
+30
+1% +$30.4K 0.58% 42
2025
Q4 		$3.03M Buy
2,821
+599
+27% +$573K 0.71% 36
2025
Q3 		$1.7M Buy
2,222
+261
+13% +$194K 0.42% 55
2025
Q2 		$1.53M Buy
1,961
+192
+11% +$149K 0.42% 56
2025
Q1 		$1.46M Sell
1,769
-83
-4% -$69.1K 0.5% 48
2024
Q4 		$1.64M Hold
1,852
– – 0.54% 42
2024
Q3 		$1.64M Hold
1,852
– – 0.53% 43
2024
Q2 		$1.68M Sell
1,852
-15
-0.8% -$12K 0.57% 39
2024
Q1 		$1.45M Sell
1,867
-3,232
-63% -$2.3M 0.53% 43
2023
Q4 		$2.97M Buy
5,099
+537
+12% +$313K 1.25% 16
2023
Q3 		$2.45M Buy
4,562
+2,676
+142% +$1.38M 1.17% 16
2023
Q2 		$884K Buy
1,886
+6
+0.3% +$2.52K 0.42% 63
2023
Q1 		$646K Sell
1,880
-7,635
-80% -$2.57M 0.33% 84
2022
Q4 		$3.48M Buy
+9,515
New +$3.37M 2.02% 5

Other funds holding LLY

Lilly Endowment
Lilly Endowment Indiananapolis, Indiana $108B AUM 53.87% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $202B AUM 37.79% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Chapin Davis's LLY Position: Q2 2026 in Review

Chapin Davis reduced its Eli Lilly (LLY) stake by 39% in Q2 2026, selling an estimated $1.13M and leaving 1,749 shares worth $2.1M. The position accounts for 0.37% of the portfolio, ranked #51.

Chapin Davis first reported a position in LLY in Q4 2022 and has held it in 15 quarters since. The position peaked at $3.48M in Q4 2022. 4,626 funds tracked by Wall St. Rank hold LLY as of Q2 2026.

  • Chapin Davis held 1,749 shares of Eli Lilly worth $2.1M as of Q2 2026.
  • Chapin Davis sold 1,102 Eli Lilly shares in Q2 2026, an estimated $1.13M.
  • Eli Lilly made up 0.37% of Chapin Davis's portfolio in Q2 2026, its #51 holding.
  • Chapin Davis first reported a position in Eli Lilly in Q4 2022 and has held it in 15 quarters since.
  • Chapin Davis's Eli Lilly position peaked at $3.48M in Q4 2022.
  • 4,626 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.

Based on Chapin Davis's 13F filing for Q2 2026, filed 7 Jul 2026.